HIF1A and melanoma: However, melanoma cells attain a drug-tolerant “idling state” after enduring MAPK inhibition (MAPKi) and this state has a metabolically Low/Low (L/L) phenotype, where both AMPK/HIF-1 activity and OXPHOS/glycolysis are minimal (189).